Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia
NCT ID: NCT02555254
Last Updated: 2025-12-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
58 participants
INTERVENTIONAL
2016-02-12
2020-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microcirculatory Perfusion in Patients With Coma After Out-of-hospital Cardiac Arrest
NCT01850485
Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardiac Arrest
NCT02390999
Pre-Hospital Cooling in Cardiac Arrest Patients
NCT00915421
Intra-arrest Therapeutic Hypothermia in Prehospital Cardiac Arrest
NCT00886184
Benefit of Hypothermia in OHCA Complicating AMI
NCT06141252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Recent progress in improving mortality and neurological outcome has been achieved over the last decade with systematic implementation of a period of targeted temperature management between 32 and 34 ° C (TTM 32-34) in patients with cardiac arrest and who benefited from the completion of at least one external electrical shock when help arrived. The mechanisms underlying this improvement of neurological prognosis are many, but mainly related to an attenuation of post resuscitation syndrome that combines in one hand an inflammatory response (mediated by pro-inflammatory cytokines including interleukin 6) and secondly the formation of reperfusion injury related to the production of radical oxygen species (free radicals).
While some studies have shown the feasibility of induction of this TTM 32-34 in prehospital conditions, no prospective study has evaluated the significant speed of warming in the end. An observational study in which the heating was carried passively, found that patients with an extended heating period (600 minutes) had a worse neurological outcome than patients with a duration of shorter warming (479 minutes) while a second retrospective study concluded the opposite in case of active warming . Besides the fact that these studies were observational, in the two originals randomized studies on TTM 32-34 in CA, the rate of warming was not like:
* Objective 6 hours with active warming is 0.5 ° C / h in the Australian study with an OR of 5.25 (1.47 - 18.76) for the neurological prognosis
* Objective 8 hours with passive warming of 0.37 ° C / h in the European study with an OR of 1.4 (1.08 - 1.81) for the neurological prognosis Although populations of two studies are obviously not comparable, it is possible that suboptimal speed of rewarming could mitigate some of the gain related to the implementation of TTM 32-34.
In this context, investigators propose to conduct a randomized, single-center pilot study comparing a fast warming in a slow warming when performing a TTM 33 patients presented with a shockable cardiac arrest.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low speed of rewarming
Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
Low Speed of Rewarming
Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
Fast speed of rewarming
Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
High Speed of Rewarming
Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low Speed of Rewarming
Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
High Speed of Rewarming
Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Coma persistent at ICU admission (Glasgow score less than or equal to 8) in the absence of sedation. If the patient is sedated in ICU admission, the glasgow score will be held the last evaluated by the doctor who provided the pre-hospital care of the patient score.
* Body temperature\> 33 ° C
* Specific device used to targeted temperature management at 33°C
Exclusion Criteria
* Duration of no-flow\> 10 minutes (time between the onset of cardiac arrest and the start of external cardiac massage).
* Duration of low-flow\> 60 minutes (the period between the start of external cardiac massage and recovery of an effective cardiac activity).
* Major hemodynamic instability (dose norepinephrine and / or epinephrine \> 1 µg / kg / min to maintain MAP\> 65 mmHg).
* Time between cardiac arrest and more than 480 minutes inclusion
* Moribund.
* Presence of histologically confirmed cirrhosis of Child class C.
* Patient treatment in blocking the production of Il6 (Ro-tocilizumab or Actemra ®)
* Patient under corticosteroid treatment (dose\> 5 mg of prednisolone equivalent)
* Pregnant woman, parturient or lactating.
* Inpatient without consent and / or deprived of liberty by a court decision.
* Patient under guardianship
* Inclusion in advance a research protocol with the draw, and whose primary endpoint is on interleukin-6.
* Lack of social security.
* Refusal of the trusted person or patient.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Departemental Vendee
OTHER
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Baptiste Lascarrou, MD
Role: STUDY_CHAIR
Nantes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Colin Gwenhael
La Roche-sur-Yon, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pouplet C, Colin G, Guichard E, Reignier J, Le Gouge A, Martin S, Lacherade JC, Lascarrou JB; AfterROSC network. The accuracy of various neuro-prognostication algorithms and the added value of neurofilament light chain dosage for patients resuscitated from shockable cardiac arrest: An ancillary analysis of the ISOCRATE study. Resuscitation. 2022 Feb;171:1-7. doi: 10.1016/j.resuscitation.2021.12.009. Epub 2021 Dec 13.
Lascarrou JB, Guichard E, Reignier J, Le Gouge A, Pouplet C, Martin S, Lacherade JC, Colin G; AfterROSC network. Impact of rewarming rate on interleukin-6 levels in patients with shockable cardiac arrest receiving targeted temperature management at 33 degrees C: the ISOCRATE pilot randomized controlled trial. Crit Care. 2021 Dec 17;25(1):434. doi: 10.1186/s13054-021-03842-9.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHD 013-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.